Skip to main content
. 2021 Jun 9;112(7):2803–2820. doi: 10.1111/cas.14976

FIGURE 5.

FIGURE 5

Disruption of HSP47 enhances NOX‐induced generation of ROS in pancreatic cancer cells after treatment with gemcitabine. A, Levels of intracellular ROS in HSP47 KO PDAC cells (HSP47 KO PANC1 cells and HSP47 KO MIA‐PaCa2 cells) treated with gemcitabine (10 μmol/L for PANC1 cells and 1 nmol/L for MIA‐PaCa2 cells). B, Expression of Nox4 protein in HSP47 KO PDAC cells. C, Expression of p22phox mRNA in HSP47 KO PDAC cells treated with gemcitabine. D, Level of NOX activity in HSP47 KO PDAC cells treated with gemcitabine. E, Levels of NOX activity in HSP47 KO PDAC cells treated with the NOX inhibitor DPI (2 μmol/L) and gemcitabine. F, Levels of intracellular ROS in HSP47 KO PDAC cells treated with the NOX inhibitor DPI (2 μmol/L) and gemcitabine. G, Viability of HSP47 KO PANC1 cells after treatment with NAC (10 μmol/L), DPI (2 μmol/L) and gemcitabine. H, IC50 values of HSP47 KO PANC1 cells after treatment with NAC (10 μmol/L), DPI (2 μmol/L) and gemcitabine. *, P < .05. n.s., not significant